FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057430675> ?p ?o ?g. }

• W2057430675 abstract "In 1932, Dr. Jean La Barre (1) of Belgium introduced “incretin” as the name of a substance in the gut mucosa that produces hypoglycemia when injected in normal but not in pancreatectomized experimental animals. He and Dr. Hans Heller (2) of Austria suggested almost simultaneously that this could be the basis for diabetes therapy. The incretin concept was further developed in the early 1960s when it became possible to determine the insulin level in blood. Then thefamousexperimentscomparingthe influenceof ivvs.oral glucoseadministrationoninsulinsecretionwereundertaken. The results showed that oral glucose elicited a much larger insulin response than an iv glucose infusion (3, 4). This was confirmed in a study when glucose levels were the same after oral vs. iv glucose administration (5) and, with similar technique, has also been demonstrated to exist in mice (6), providing a tool for investigating incretin mechanisms in more detail. The incretin function has key physiological impact on glucose homeostasis after oral glucose. This is illustrated by results in healthy humans that the glucose excursion is very similar after ingestion of 25, 50, or 100 g due to an increase in the incretin effect matching the increased glucose load and preventing hyperglycemia (5). The incretin effect is largely attributed to the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). They are both released from enteroendocrine cells after oral glucose, and they both augment glucose-stimulated insulin secretion (7). GIP and GLP-1 are also released after ingestion of nonglucose macronutrients (both proteins and lipids) (8). This may suggest that the incretin concept is broader than only augmenting insulin secretion after oral glucose. However, whether the incretin hormones are of importance for the insulin response to nonglucose stimuli also remains to be established. Duringrecentyears, the interest inthe incretinconcepthas been intensified because pharmacological therapy of type 2 diabetes has been developed based on the antidiabetic action of GLP-1 (9). In addition to stimulated insulin secretion, these actions include inhibited glucagon secretion, induction of satiety, and delay in gastric emptying. Today, clinically introduced incretin-based therapy exists in terms of injectable GLP-1 receptor agonists and of orally available inhibitors of the enzyme dipeptidyl peptidase-4 (DPP-4), which raise endogenous GIP and GLP-1 levels by preventing inactivation of the incretin hormones (9). An important discussion has evolved as to whether the incretin function is impaired in type 2 diabetes and, if so, whether this contributes to the pathophysiology of the disease. A first study on this topic compared the insulin and C-peptide responses to oral glucose (50 g) vs. iv glucose when plasma glucose levels were matched, and the study was performed in both healthy subjects and subjects with type 2 diabetes (10). The results showed that more than 70% of the insulin response to oral glucose was mediated by the incretin hormones in healthy subjects,whereas the corresponding figure in subjectswith type 2 diabetes was less than 40%, i.e. the results suggested that incretin function is markedly impaired in type 2 diabetes. At the same time, the study showed that the GIP response to oral glucose was the same in healthy and diabetic subjects (GLP-1 was not determined). Therefore, this study suggested that it is impaired action of incretin hormones rather than impaired incretin hormone secretion that explains the defective incretin function in type 2 diabetes. This conclusion was supported by other results showing that the insulin secretory response to iv GIP is indeed markedly impaired in type 2 diabetes (11). It was later shown that the insulinotropic action of iv GLP-1 is also impaired in type 2 diabetes, albeit not as much as the response to GIP (12). Other studies have, however, shown defective incretin hormone secretion in type 2 diabetes, making this" @default.
• W2057430675 created "2016-06-24" @default.
• W2057430675 creator A5027109387 @default.
• W2057430675 date "2011-03-01" @default.
• W2057430675 modified "2023-09-23" @default.
• W2057430675 title "The Dynamic Incretin Adaptation and Type 2 Diabetes" @default.
• W2057430675 cites W1798566282 @default.
• W2057430675 cites W1969932276 @default.
• W2057430675 cites W1975591028 @default.
• W2057430675 cites W1994989824 @default.
• W2057430675 cites W2002800136 @default.
• W2057430675 cites W2004977380 @default.
• W2057430675 cites W2032264656 @default.
• W2057430675 cites W2041551639 @default.
• W2057430675 cites W2054564814 @default.
• W2057430675 cites W2089304685 @default.
• W2057430675 cites W2100816243 @default.
• W2057430675 cites W2104938107 @default.
• W2057430675 cites W2133408552 @default.
• W2057430675 cites W2140978079 @default.
• W2057430675 cites W2147817624 @default.
• W2057430675 cites W2169274492 @default.
• W2057430675 cites W2921730124 @default.
• W2057430675 doi "https://doi.org/10.1210/jc.2011-0299" @default.
• W2057430675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21378226" @default.
• W2057430675 hasPublicationYear "2011" @default.
• W2057430675 type Work @default.
• W2057430675 sameAs 2057430675 @default.
• W2057430675 citedByCount "6" @default.
• W2057430675 countsByYear W20574306752012 @default.
• W2057430675 countsByYear W20574306752013 @default.
• W2057430675 countsByYear W20574306752014 @default.
• W2057430675 countsByYear W20574306752015 @default.
• W2057430675 countsByYear W20574306752022 @default.
• W2057430675 crossrefType "journal-article" @default.
• W2057430675 hasAuthorship W2057430675A5027109387 @default.
• W2057430675 hasBestOaLocation W20574306751 @default.
• W2057430675 hasConcept C126322002 @default.
• W2057430675 hasConcept C134018914 @default.
• W2057430675 hasConcept C193230392 @default.
• W2057430675 hasConcept C2776129832 @default.
• W2057430675 hasConcept C2776398474 @default.
• W2057430675 hasConcept C2777180221 @default.
• W2057430675 hasConcept C2777391703 @default.
• W2057430675 hasConcept C2778563252 @default.
• W2057430675 hasConcept C2778881409 @default.
• W2057430675 hasConcept C2779306644 @default.
• W2057430675 hasConcept C2780668416 @default.
• W2057430675 hasConcept C3018667095 @default.
• W2057430675 hasConcept C555293320 @default.
• W2057430675 hasConcept C71924100 @default.
• W2057430675 hasConceptScore W2057430675C126322002 @default.
• W2057430675 hasConceptScore W2057430675C134018914 @default.
• W2057430675 hasConceptScore W2057430675C193230392 @default.
• W2057430675 hasConceptScore W2057430675C2776129832 @default.
• W2057430675 hasConceptScore W2057430675C2776398474 @default.
• W2057430675 hasConceptScore W2057430675C2777180221 @default.
• W2057430675 hasConceptScore W2057430675C2777391703 @default.
• W2057430675 hasConceptScore W2057430675C2778563252 @default.
• W2057430675 hasConceptScore W2057430675C2778881409 @default.
• W2057430675 hasConceptScore W2057430675C2779306644 @default.
• W2057430675 hasConceptScore W2057430675C2780668416 @default.
• W2057430675 hasConceptScore W2057430675C3018667095 @default.
• W2057430675 hasConceptScore W2057430675C555293320 @default.
• W2057430675 hasConceptScore W2057430675C71924100 @default.
• W2057430675 hasLocation W20574306751 @default.
• W2057430675 hasLocation W20574306752 @default.
• W2057430675 hasLocation W20574306753 @default.
• W2057430675 hasLocation W20574306754 @default.
• W2057430675 hasOpenAccess W2057430675 @default.
• W2057430675 hasPrimaryLocation W20574306751 @default.
• W2057430675 isParatext "false" @default.
• W2057430675 isRetracted "false" @default.
• W2057430675 magId "2057430675" @default.
• W2057430675 workType "article" @default.